Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public debate.

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

Nearly half of Americans find weight loss challenging. If you’re struggling with weight loss, then you've likely experimented with new diet ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...